NASDAQ:ABCL

Abcellera Biologics Stock News

etoro logo Buy ABCL
*Your capital is at risk
$5.80
-0.665 (-10.29%)
At Close: Jul 20, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Victor Sandor to its Board of Directors.
AbCellera Biologics NASDAQ: ABCL is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said dur
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
From a technical perspective, AbCellera Biologics Inc. (ABCL) is looking like an interesting pick, as it just reached a key level of support. ABCL's 50-day simple moving average crossed above its 200-
The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, th
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued prepar
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.15 per share a year ago.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE